Gastric mucosal injury and hemorrhage after definitive chemoradiotherapy for locally advanced esophageal cancer
- 36 Downloads
Definitive chemoradiotherapy is one of the treatment options for locally advanced esophageal cancer with curative intent. Esophagitis and pharyngitis are well-known adverse events that occur during chemoradiotherapy, but gastric mucosal injury has been less frequently reported compared to mucositis. Importantly, gastric mucosal injury is not well known, hard to manage, and sometimes fatal. Hence, we examined the clinical characteristics and the incidence of gastric mucosal injury after CRT for esophageal cancer.
The medical records of patients who received definitive chemoradiotherapy combined with 5-fluorouracil and cisplatin for stage II/III (nonT4) esophageal squamous cell carcinoma from January 2001 to December 2010 at our institute were reviewed retrospectively.
We investigated 256 patients in whom, data for endoscopic abdomen examinations were both before and after CRT were available. Gastric mucosal damage was observed in 90 patients (35%) (grade 1/2/3 = 69/18/3). One of the possible risk factors identified in this study was the irradiation dose to abdomen. Compared to patients with cervical esophagus–upper thoracic esophagus tumor location, patients with middle thoracic esophagus–abdominal esophagus tumor location were more likely to develop gastric mucosal damage, although there was no statistically significant difference.
It is important to consider gastric mucosal injury in patients who receive CRT, particularly when the irradiation field includes stomach.
KeywordsEsophageal cancer Chemoradiotherapy Mucosal injury Stomach
This study was supported by the National Cancer Center Research and Development Fund (26-A-4). We thank Dr. Nobukazu Hokamura for collecting the data used in this study.
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Ethics approval was obtained from National Cancer Center Hospital's review board (NCC2012-268).
- 9.Nakamura A, Shibuya K, Matsuo Y, et al. Analysis of domestic parameters associated with acute gastrointestinal toxicity and upper gastrointestinal bleeding in locally advanced pancreatic cancer patients treated with Gemcitabine-based concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2012;84:369–75.CrossRefGoogle Scholar
- 10.Maráz A, Furák J, Varga Z, et al. Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for non-small cell lung cancer. Anticancer Res. 2013;33:1737–41.Google Scholar